by James Lyons-Weiler, PhD, Popular Rationalism, ©2026
(Apr. 23, 2026) — There is a difference between disagreement and distortion. Several senators crossed that line in their attacks on Secretary Kennedy’s measles testimony. They did not merely disagree with him. They used Senatorial rhetoric to treat a technically demanding surveillance problem as though it were morally self-interpreting, then acted as if indignation could substitute for laboratory method.
That is not oversight. That is theater.
At the April 22, 2026 Senate Finance Committee hearing, Sen. Ron Wyden attacked Kennedy’s vaccine messaging in sweeping terms: “When it comes to vaccines, Robert Kennedy has used this once-in-a-lifetime platform to make parents doubt themselves and doubt their doctors,” adding that Kennedy had failed to say “what needs to be said: vaccines save lives in America.” Sen. Michael Bennet pressed Kennedy on prior flu-vaccine rhetoric, then asked whether Kennedy was “taking the position that the measles vaccine is vital to keeping American children healthy in this country.” Kennedy answered, “That’s my position,” and added, “We promote the measles vaccine.” Sen. Ben Ray Luján likewise pressed him on measles and MMR uptake, and Kennedy answered: “We promote the MMR. We advise every child to get the MMR.” Those are not ambiguous statements. They are not anti-MMR statements. Any senator or commentator who recasts that exchange as a refusal to support measles vaccination is not clarifying the record. He is rewriting it.
Now to the science the senators flattened.
Measles surveillance is not supposed to rest on visual diagnosis, emotional certainty, or the simple existence of a rash. It rests on case classification, laboratory confirmation, and—when needed—molecular differentiation. That last point matters more than Kennedy’s critics seem willing to admit. Roy and colleagues developed a real-time RT-PCR assay specific for genotype A measles virus, the vaccine genotype, precisely because public-health investigators need to distinguish vaccine-associated detections from wild-type measles quickly and accurately. CDC’s own MeVA assay guidance cites Roy et al. for that purpose. The point is elementary but consequential: if vaccine-strain detections are not rapidly separated from wild-type infection, investigators can misclassify events, trigger unnecessary response measures, and communicate public numbers as though every counted event carries the same evidentiary weight when it does not.
Read the rest here.